On January 11, 2023, at the beginning of the New Year, the capping ceremony of the drug research and development and production base of Hangzhou Yuanxi Pharmaceutical Technology Co., Ltd. was officially opened in Yaogang Town, Qiantang District, Hangzhou. Dr. Xu Qi, CEO of Teide Medicine, Dr. Tang Yu, General manager of Yuanxi Medicine, leaders of construction units, leaders of supervision units, and leaders and colleagues of Chinese peptide company were invited to attend and witness a moment of glory and joy.
At 10:08 a.m., the leaders of the three parties attended the meeting waved the golden shovel together and poured the last concrete for the main project of Yuanxi Medicine, which marked the building entered the decoration stage comprehensively and meant that it was one step closer to the completion of the modern base.
At 10:20, Dr. Xu Qi, CEO of TateMed, delivered a speech. The completion of the R&D and production base of Yuanxi Pharmaceuticals is an important part of the future strategic development of Tate Pharma, and is an important milestone for the integration of biochemical raw materials and preparations of Chinese peptide company and innovation-driven development. At the same time, Dr. Xu Qi, CEO of TateMed, expressed his full affirmation and heartfelt gratitude for the efforts and contributions made by the construction, design, survey, supervision and quality supervision and inspection agencies involved in the project construction. We hope that the construction unit will continue to carry forward its consistent style, and all participating units will continue to strengthen their collaboration, further tighten the safety and quality control, and organize and implement the follow-up works to ensure the successful completion of the overall construction task of Yuanxi. Finally, Dr. Xu Qi once again thanked everyone for their great support in the construction of Yuanxi drug development and production base and expressed his best wishes for the Chinese New Year.
The topping-out ceremony marks the completion of the new leap from blueprint to reality, and confirms the Group's vigorous development pattern of flourishing industries. In the future, TED Pharmaceutical Group will work together with Yuanxi Pharmaceutical through CPCB to build a reliable global integrated peptide and nucleic acid CRDMO partner through the integration of international cutting-edge peptide and nucleic acid drug raw materials, and to help our partners to develop drugs for patients in a more compliant, safe and efficient way.
Hangzhou Yuanxi Pharmaceutical Technology Co., Ltd. was established in Hangzhou Pharmaceutical Port Town in December 2020, and is a high-tech enterprise led by national and provincial special experts. The project covers an area of 15 mu, with a building area of about 26,700m2. Upon completion, the project will form a modern drug R&D and production base with a ten-story above-ground building and a three-story podium.